Back to results
US 2019/0094221 A1Published application
N-acetyl-d-glucosamine for enhanced specificity of strep a immunoassay
AssigneeQuidel Corporation
InventorsPeter Yan-Guo REN, Jason MCCLURE, Kevin S. RICHARDSON
Life of this patent
Estimating the term…
Abstract
Methods, compositions and kits for detecting Group A streptococcus in a biological sample are described. More particularly, the present disclosure provides an immunoassay in which the specificity of detection of Group A streptococcus is enhanced by addition of N-acetyl-D-glucosamine. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of streptococcal infection in a human subject.
Claims20
A device, comprising:
- a matrix comprising (i) a sample receiving zone, (ii) a labeling zone comprising a labeled antibody with specific binding to Group A streptococcus antigen, to form a labeled antibody-bound antigen, and (iii) a capture zone comprising a capture antibody that binds the labeled antibody-bound antigen, wherein the sample receiving zone, the labeling zone and the capture zone are arranged on the matrix in a liquid flow path, and
- wherein at least one of the sample receiving zone and the labeling zone comprise N-acetyl-D-glucosamine (NAG) monomer to reduce the rate of false positives associated with detection of Group A streptococcus infection.
A device, comprising:
- a matrix comprising (i) a sample receiving zone, (ii) a labeling zone comprising a labeled antibody with specific binding to Group A streptococcus antigen, to form a labeled antibody-bound antigen, and (iii) a capture zone comprising a capture antibody that binds the labeled antibody-bound antigen, wherein the sample receiving zone, the labeling zone and the capture zone are arranged on the matrix in a liquid flow path, and
- wherein at least one of the sample receiving zone and the labeling zone comprise a reagent that blocks binding of the labeled antibody with specific binding to Group A streptococcus antigen with human epithelial cell wall glycoproteins, to reduce the rate of false positives associated with detection of Group A streptococcus infection.
Dependencies are inferred from the claim text.